Literature DB >> 30168294

Alternate gas washout indices: Assessment of ventilation inhomogeneity in mild to moderate pediatric cystic fibrosis lung disease.

Sylvia Nyilas1,2, Anja Bigler2, Sophie Yammine2, Elisabeth Kieninger2, Isabelle Rochat3, Kathryn Ramsey2, Carmen Casaulta2, Alexander Moeller1, Philipp Latzin2, Florian Singer1,2.   

Abstract

INTRODUCTION: Normalized phase III slope (SnIII ) indices from multiple breath washout (MBW) estimate ventilation inhomogeneity. Alternate (*) protocols for SnIII indices exist, however the utility of these outcomes in children with mild-to-moderate cystic fibrosis (CF) is unknown.
METHODS: We measured nitrogen MBW and spirometry in 135 children (43 controls) aged 4-18 years. We assessed validity, practicability, and reliability of SnIII protocols. Outcomes included the ability to detect abnormal lung function, test agreement, measurement duration, intra-test repeatability, and quality.
RESULTS: Lung clearance index (LCI) was abnormal in 80 (87%), Scond in 55 (60%), Scond* in 17 (19%), Sacin in 10 (11%), Sacin* in 11 (12%), and FEV1 in 28 (30%). Alternate protocols reduced measurement duration. Agreement of indices to detect abnormal lung function was poor. The quality of analysis and repeatability deteriorated with the alternate technique compared to standard.
CONCLUSION: In children with mild-to-moderate CF lung disease, alternate protocols seem practical but clinimetric properties of standard SnIII protocols are preferable.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  child; cystic fibrosis; lung function tests

Mesh:

Year:  2018        PMID: 30168294     DOI: 10.1002/ppul.24149

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  1 in total

1.  A multi-scale model of gas transport in the lung to study heterogeneous lung ventilation during the multiple-breath washout test.

Authors:  David Hasler; Pinelopi Anagnostopoulou; Sylvia Nyilas; Philipp Latzin; Johannes Schittny; Dominik Obrist
Journal:  PLoS Comput Biol       Date:  2019-06-17       Impact factor: 4.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.